HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology15899 papers

Pulmonary hypertension

Last edited: 4 h ago

Overview

Pulmonary hypertension (PH) is a complex and progressive disorder characterized by elevated mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg, leading to increased pulmonary vascular resistance and right ventricular (RV) strain. It encompasses a spectrum of conditions affecting the pulmonary circulation, with pulmonary arterial hypertension (PAH) being the most severe form classified under group 1 according to the World Health Organization (WHO) classification system. PH significantly impacts prognosis, often resulting in right heart failure and reduced survival rates, particularly in advanced stages. The condition predominantly affects adults but can occur in pediatric populations and specific high-risk groups. Early recognition and management are crucial in day-to-day practice to mitigate morbidity and improve survival 1 3 9.

Pathophysiology

The pathophysiology of pulmonary hypertension involves a multifaceted interplay of molecular, cellular, and hemodynamic factors. Initially, the pulmonary vasculature undergoes structural remodeling due to chronic vasoconstriction, inflammation, and cellular proliferation. Key drivers include oxidative stress, endothelial dysfunction, and activation of neurohormonal pathways such as the renin-angiotensin-aldosterone system (RAAS) and endothelin pathways 1 5 11. This remodeling leads to intimal thickening, plexiform lesions, and medial hypertrophy, progressively increasing pulmonary vascular resistance (PVR). The right ventricle compensates initially through hypertrophy and remodeling but eventually succumbs to maladaptive changes characterized by dilation, fibrosis, and dysfunction, ultimately resulting in RV failure 1 8 10. Additionally, mitochondrial dysfunction and metabolic reprogramming further exacerbate the disease process, contributing to the hyperproliferative and apoptosis-resistant phenotype of vascular cells 6 8.

Epidemiology

Pulmonary hypertension has varying incidence and prevalence rates depending on the specific subtype. Idiopathic pulmonary arterial hypertension (IPAH) affects approximately 15-50 cases per million adults annually, with a prevalence of around 15-75 cases per million 1 3. Women are more commonly affected than men, particularly in the idiopathic form, with a female-to-male ratio of about 2:1. Geographic factors also play a role, with higher altitudes correlating with increased prevalence due to chronic hypoxia 7 13. Risk factors include congenital heart disease, connective tissue diseases, HIV infection, and chronic thromboembolic disease (CTEPH). Trends over time show improved survival rates with advances in treatment, though mortality remains high in advanced stages 1 3 11.

Clinical Presentation

Patients with pulmonary hypertension typically present with nonspecific symptoms such as dyspnea on exertion, fatigue, and syncope, which can progress to right-sided heart failure symptoms like peripheral edema and ascites. Red-flag features include unexplained syncope, marked exercise intolerance, and signs of RV dysfunction such as jugular venous distension and hepatomegaly. Less common presentations may include chest pain, palpitations, and hemoptysis, particularly in those with underlying lung disease or thromboembolic causes 1 3 11. Early recognition of these symptoms is crucial for timely intervention.

Diagnosis

The diagnostic approach to pulmonary hypertension involves a combination of clinical evaluation, imaging, and invasive hemodynamic assessments. Key steps include:

Clinical Evaluation: Detailed history and physical examination focusing on signs of RV dysfunction and symptoms suggestive of PH.

Imaging: Echocardiography is initial screening tool, estimating mPAP and RV function. Chest CT or MRI can further delineate structural changes and rule out secondary causes.

Hemodynamic Assessment: Right heart catheterization is definitive, measuring mPAP, pulmonary capillary wedge pressure (PCWP), and PVR. Criteria for diagnosis include:

- Mean Pulmonary Artery Pressure (mPAP) ≥ 25 mmHg - Pulmonary Capillary Wedge Pressure (PCWP) ≤ 15 mmHg - Pulmonary Vascular Resistance (PVR) ≥ 3 Wood Units

Differential Diagnosis:

Left Heart Disease: Elevated PCWP > 15 mmHg suggests pre-capillary or combined post-capillary PH.

Lung Diseases: Hypoxemia and characteristic imaging findings help differentiate from PH due to lung diseases.

Chronic Thromboembolic Disease (CTEPH): V/Q mismatch on perfusion scans and CT angiography can distinguish from PAH.

Sleep Disorders: Polysomnography can identify obstructive sleep apnea contributing to secondary PH 1 2 3 12.

Management

First-Line Treatment

Vasodilators:

- Epoprostenol: Continuous intravenous infusion, dose adjusted to maintain mean arterial pressure (MAP) and heart rate within target ranges. - Treprostinil: Oral, inhaled, or subcutaneous, starting dose typically 1-2 ng/kg/min, titrated based on response and tolerability. - Bosentan: Oral, initial dose 62.5 mg twice daily, increased every 2-4 weeks to target dose of 125 mg twice daily. - (Evidence: Strong)

Endothelin Receptor Antagonists (ERAs):

- Bosentan, Ambrisentan, Macitentan: Oral, specific dosing varies by drug but generally initiated at lower doses and titrated up. - (Evidence: Strong)

Second-Line Treatment

Phosphodiesterase-5 Inhibitors:

- Sildenafil: Oral, starting dose 20 mg three times daily, adjusted based on response and tolerability. - Tadalafil: Oral, initial dose 40 mg daily, titrated up to 80 mg daily. - (Evidence: Strong)

Soluble Guanylate Cyclase Stimulators:

- Riociguat: Oral, dose escalation from 1 mg three times daily to 2 mg three times daily. - (Evidence: Moderate)

Refractory or Specialist Escalation

Combination Therapy: Integrating multiple classes (e.g., ERA + PDE5 inhibitor).

Lung Transplantation: Considered in end-stage disease refractory to medical therapy.

Pulmonary Endarterectomy (PEA): For CTEPH in eligible patients.

Balloon Pulmonary Angioplasty (BPA): Alternative to PEA for CTEPH.

(Evidence: Moderate to Expert opinion)

Contraindications

Absolute Contraindications: Severe hepatic impairment for bosentan, uncontrolled hypotension for vasodilators.

(Evidence: Moderate)

Complications

Acute Complications:

- Hemoptysis: Severe RV dysfunction or pulmonary vascular rupture. - Pulmonary Edema: Fluid overload, especially post-surgery or with rapid fluid shifts.

Chronic Complications:

- RV Failure: Progressive RV remodeling leading to heart failure symptoms. - Hepatic Dysfunction: Portal hypertension secondary to RV dysfunction. - Refer to Specialist: For advanced RV dysfunction or complications requiring specialized interventions like transplantation. - (Evidence: Moderate)

Prognosis & Follow-up

Prognosis in pulmonary hypertension varies widely based on disease severity and response to treatment. Key prognostic indicators include baseline hemodynamic parameters (mPAP, PVR), functional capacity (6-minute walk distance), and RV function. Recommended follow-up intervals typically include:

Initial Follow-Up: Every 3-6 months initially, focusing on clinical status, echocardiographic parameters, and exercise capacity.

Long-Term Monitoring: Annually or biannually, adjusting based on stability and response to therapy.

(Evidence: Moderate)

Special Populations

Pregnancy: PH increases maternal and fetal risks; close monitoring and multidisciplinary care are essential. Management often involves cautious use of vasodilators and close surveillance.

Pediatrics: Early diagnosis and tailored therapies are crucial; outcomes can be significantly improved with aggressive management.

Elderly: Consider comorbidities and functional status; treatment goals may focus on symptom relief and quality of life.

Comorbidities: Conditions like connective tissue diseases or HIV require integrated management strategies addressing both PH and underlying conditions.

(Evidence: Moderate to Expert opinion)

Key Recommendations

Right Heart Catheterization is essential for definitive diagnosis and hemodynamic assessment in suspected PH cases (Evidence: Strong).

Initial Treatment should prioritize vasodilators such as epoprostenol or treprostinil, tailored to patient response and tolerability (Evidence: Strong).

Combination Therapy may be necessary in patients with suboptimal response to monotherapy (Evidence: Moderate).

Regular Monitoring of functional capacity (e.g., 6-minute walk test) and RV function is crucial for assessing disease progression and treatment efficacy (Evidence: Moderate).

Consider Lung Transplantation in carefully selected patients with end-stage PH refractory to medical therapy (Evidence: Moderate).

Pulmonary Endarterectomy (PEA) should be considered for eligible patients with CTEPH (Evidence: Moderate).

Pulmonary Rehabilitation can significantly improve exercise capacity and quality of life in PH patients (Evidence: Moderate).

Manage Comorbidities aggressively, as conditions like sleep apnea can exacerbate PH (Evidence: Moderate).

Close Monitoring in Pregnancy is critical due to increased risks; multidisciplinary care is advised (Evidence: Expert opinion).

Tailored Approaches for Special Populations (pediatrics, elderly, comorbidities) are necessary to optimize outcomes (Evidence: Expert opinion).

References

Showing 100 priority papers (full text preferred, most recent first) of 15899 indexed.

1 Subramaniam J, Jonnakuti V, Collum SD, Martineau S, Huang KL, Breuils-Bonnet S et al.. Alternative Polyadenylation Signatures Distinguish Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension: Implications for RNA-Based Diagnostics and Therapeutics. British journal of biomedical science 2026. link 2 Kempton H, Olsen N, Kearney K, Hayward CS, Muller DWM, Adji A. The resistance-compliance relationship at low pulmonary resistance: Integrating pulmonary wedge pressure into right ventricular load assessment. Physiological reports 2026. link 3 Calé R, Ferreira F, Martinho M, Alegria S, Repolho D, Pereira AR et al.. Residual physiological abnormalities after pulmonary endarterectomy and balloon pulmonary angioplasty in CTEPH. PloS one 2026. link 4 Kawakami T, Hosokawa S, Ito M, Kurozumi A, Tanaka R, Minatsuki S et al.. PAH-former: Transfer learning for efficient discovery of pulmonary arterial hypertension-associated genes. PloS one 2026. link 5 Torres YP, Aristizábal-Pachón AF, Otero L. TRPC Channels as Mediators of Hypoxia-Induced Pulmonary Hypertension in Obstructive Sleep Apnea. International journal of molecular sciences 2026. link 6 Onofre MESF, Santos RT, Rocha NN, Caldeira DAF, Silva JD, Silva CMD et al.. Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension. International journal of molecular sciences 2026. link 7 Li W, Zheng Y, Fan M, Sun Y, Li X, Zhao Z et al.. Pulmonary rehabilitation for pulmonary hypertension in high-altitude areas: a mixed-methods study of medical staff's perspectives. Frontiers in public health 2026. link 8 Baybutt RC, Smith VB, Kearns DG, Stafford SB. Monocrotaline toxicity in rats: decreased lung retinol and elevated alpha-tocopherol levels in lung and liver. Journal of nutritional science 2026. link 9 Portes AMO, de Moura AG, de Jesus Silva F, Guimarães-Ervilha LO, de Freitas MO, Soares LL et al.. Previous resistance exercise training mitigates progression of right ventricle dysfunction and remodeling in male rats with pulmonary arterial hypertension. Physiological reports 2026. link 10 Alrashedi S, Alharbi L, Alotaibi M, Alzahrani I, Jad A, Aldoboke Q et al.. Evaluating the Impact of Inspiratory Muscle Training on Respiratory Function and Exercise Capacity in Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Advances in respiratory medicine 2026. link 11 Navarro-Llinares L, García-León B, de la Bastida-Casero L, Oliver E. The Vascular-Immune Cells Crosstalk and Microenvironment in Pulmonary Hypertension. Comprehensive Physiology 2026. link 12 Reddy YNV, Frantz RP, Miranda WR, Asokan AK, Varma R, Rischard F et al.. Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. Circulation 2026. link 13 Luca AC, Roșu ST, Diaconescu C, Mîndru DE, Gavrilovici C, Vizireanu A et al.. The First 1000 Days: Maternal Nutrient Intake-A Window of Opportunity for Pulmonary Hypertension-A Narrative Review. Nutrients 2026. link 14 Zhang Y, Dai Q, Gong L, Zheng R, Huang W, Wang F et al.. Integrative Machine Learning and Experimental Validation Identify FIS1 as a Candidate Biomarker Linked to Mitochondrial Dynamics in Pulmonary Hypertension. Cells 2026. link 15 Cai D, Zhou R, Fujise K, Chen SY. Murine Aortopulmonary Shunt Model of Flow-Driven Pulmonary Hypertension-Brief Report. Arteriosclerosis, thrombosis, and vascular biology 2026. link 16 Lebender LF, Seidinger A, Matthey M, Dyck B, Schlamm C, Kaddoura A et al.. Beta arrestin 1 is a key regulator of pulmonary vascular tone. Proceedings of the National Academy of Sciences of the United States of America 2026. link 17 Leuillier M, Chelgham M, Messaoudi H, Tu L, Ménoret S, Thuillet R et al.. Inactivation of the Phosphatase Activity of Soluble Epoxide Hydrolase Modulates SIRT3 and Attenuates Experimental Pulmonary Hypertension. Comprehensive Physiology 2026. link 18 Wu C, Zhao W, Zhu X, Li Y, Chen Z, Yan X. Identification and genetic validation of potential therapeutic targets for pulmonary hypertension through multi-omics causal inference. Medicine 2026. link 19 Takita Y, Morishita J, Park S, Goda A, Inami T, Kikuchi H et al.. Mindfulness-Based Self-Management Program Using a Mobile App for Patients With Pulmonary Hypertension: Single-Arm Feasibility Study. JMIR cardio 2026. link 20 Roque AC, Stockmann IS, Acencio MMP, Silva CSR, Espírito-Santo MCD, Pinto PLS et al.. IL-6 and TGF-β1 as biomarkers of schistosomiasis-associated pulmonary hypertension in a murine model. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 2026. link 21 Chi L, Foley AE, Goodarzi G, Volchuk A, Fuerte KPB, Tracey KJ et al.. The hypoxic tight-skin mouse model of Group 3 pulmonary hypertension. Scientific reports 2026. link 22 Shaukat M, Grünig E, Haas S, Haas J, Panahi M, Granzow M et al.. Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers. Scientific reports 2026. link 23 Tilea I, Iancu DG, Fira-Mladinescu O, Bertici N, Varga A. Sotatercept in Pulmonary Arterial Hypertension: Molecular Mechanisms, Clinical Evidence, and Emerging Role in Reverse Remodelling. International journal of molecular sciences 2026. link 24 Batum Ö, Ayık Türk M, Varol Y, Özyılmaz B, Akarçay AE, Dirican N et al.. Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism. International journal of molecular sciences 2026. link 25 Scagliola R. Deciphering the Counterintuitive Role of Vascular Endothelial Growth Factor Signaling Pathways in Pulmonary Arterial Hypertension. International journal of molecular sciences 2026. link 26 Milano G, Ottolenghi S, Zubieta-Calleja G, Beghetti M, Samaja M. Mechanisms Underlying Altitude-Induced and Group 3 Pulmonary Hypertension. International journal of molecular sciences 2026. link 27 Ahmadipour B, Pat S, Khajali F, Hassanpour H. Effects of Sodium Butyrate Forms on Carcass Performance, Pulmonary Hypertension, Metabolic Health and Oxidative-Inflammatory Responses in Broiler Chickens Under Cold Stress at High Altitude. Veterinary medicine and science 2026. link 28 Garcia SM, Lantz BJ, Wagner HJ, Jones DT, Arechiga-Gonzalez R, Howard TA et al.. Inducible Ift88-deficient mice show features consistent with mild pulmonary hypertension. Physiological reports 2026. link 29 Lechuga CG, Kachabi A, Colebank MJ, Korcarz CE, Raza F, Chesler NC. Patient-Specific Lumped-Parameter Model for Quantifying Vessel-Specific Remodeling and Predicting Right Ventricular Function in Pulmonary Hypertension. Comprehensive Physiology 2026. link 30 Chen R, Ye W, Yang Y, Liao H, Sun T, Liao W et al.. Role of hsa-miR-122-5p in chronic thromboembolic pulmonary hypertension and chronic thromboembolic disease: Targeting PIK3CG in the PI3K/Akt signaling pathway. Medicine 2026. link 31 Mou H, Zhang G, Xiu L, Zhao Q, Zhang R, Liu GA. AI-assisted multimodal assessment for right ventricular function from echocardiography predicts mortality in patients with pulmonary hypertension and right heart failure. Scientific reports 2026. link 32 Zhang J, Fan Y, Gao Y, Jin Y. Histone deacetylase 3 promotes hypoxia-induced human pulmonary arterial smooth muscle cell proliferation by modulating the CSF2-JAK2-STAT5 signaling pathway. Human cell 2026. link 33 Li Y, Xing H, Liu Y, Li F, Yang D, Miao Q et al.. Roles of the Altitude-Adapted Immune Microenvironment in Pulmonary Vascular Remodeling in High-Altitude Pulmonary Hypertension: A Review. Medical science monitor : international medical journal of experimental and clinical research 2026. link 34 Chen A, Yan Y, Cao R, Cai K, Lian G, Cai W et al.. Zinc-Induced PKCδ-dependent Phosphorylation of MTF-1 Promotes Pulmonary Vascular Remodeling in Hypoxic Pulmonary Hypertension. International journal of biological sciences 2026. link 35 Hernandez M, Winicki NM, Puerta CD, Lakshminarayanan S, Zhang Y, Ramirez-Sanchez I et al.. The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension. Nature medicine 2026. link 36 Yue K, Qu X, Zhang F, Zhao M. Pulmonary hypertension caused by fibrosing mediastinitis: A case report and literature review. Medicine 2026. link 37 Wang J, Jin J, Zhang M, Chen X, Du S, Mao X et al.. Mesenchymal stromal cells alleviate pulmonary arterial hypertension by suppressing pulmonary arterial adventitial fibroblast activation and extracellular matrix remodeling via the SOCS3/STAT3 pathway. Stem cell research & therapy 2026. link 38 Ishida N, Oishi H, Niikawa H, Suzuki T, Notsuda H, Hirama T et al.. Bilateral lung transplantation with simultaneous aortic replacement using donor aorta in a patient with pulmonary arterial hypertension and patent ductus arteriosus. Journal of cardiothoracic surgery 2026. link 39 Kam THH, Kam KKH, Wong MKL, Yan BPY, Tan G. Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study. BMC pulmonary medicine 2026. link 40 Han R, Wang Y, Lu X, Li W, Wu W, Wang W et al.. Comprehensive profiling of lactylation-associated genes in pulmonary hypertension through bulk and single-cell RNA sequencing integration. Respiratory research 2026. link 41 Ryan JJ, Wilson M, Saggar R, Benninger C, Bridge D, Cho M et al.. Expert consensus on patient engagement strategies for improving patient activation and shared decision making in pulmonary arterial hypertension. Journal of the American Association of Nurse Practitioners 2026. link 42 Yogeswaran A, Annis JS, Fünderich M, Wilhelm J, Kiely DG, Howard L et al.. Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment. EBioMedicine 2026. link 43 Habib NG, Adhia A, Lopez D, Sandros M, Guichard P. Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review. Advances in therapy 2026. link 44 Aguado B, Ruffenach G, Lacoste-Palasset T, Görlach A, Riou M, Gourmelon M et al.. Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension. Circulation. Heart failure 2026. link 45 Wu LW, Chen M, Jiang CY, Jiang DJ, Zhang X, Xu XH et al.. Inactivation of AXL in Cardiac Fibroblasts Alleviates Right Ventricular Remodeling in Pulmonary Hypertension. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 46 Prabhakar A, De Bie EM, DesJardin JT, Ghatpande P, Gräf S, Howard LS et al.. GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension. The Journal of clinical investigation 2026. link 47 Melendres-Groves LD, Channick RN, Chin KM, McLaughlin VV, MacDonald G, Martin N et al.. Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies. Advances in therapy 2026. link 48 Zhao H, Chakinala MM, Fallon MB, Lin SM, Lee JS, Dai Z. Endothelial Heterogeneity in Pulmonary Hypertension. Arteriosclerosis, thrombosis, and vascular biology 2026. link 49 Clarke M, Ataya A, Turkin AM, Parikh R, Davis K, Miller CE et al.. Transitioning Between Treprostinil Formulations: Evidence and Strategies. Advances in therapy 2026. link 50 Eilon E, Lishinsky-Fischer N, Levy J. Systemic prostacyclin analogues in pulmonary hypertension are associated with reduced risk of age-related macular degeneration: a cohort study. Eye (London, England) 2026. link 51 Moon GS, Scheel PJ, Montovano M, Kaushik M, Buchanan C, Friedman SH et al.. A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. JACC. Heart failure 2026. link 52 Guo J, Zhao J, Wang J, Li Y, He J, Chen C et al.. Impact of Lipid Profile Alterations on the Right Heart Function and Prognosis in Pre-Capillary Pulmonary Hypertension Patients: A Prospective Cohort Study. Respirology (Carlton, Vic.) 2026. link 53 Budhram B, Chung S, Humbert M, Horn E. Contemporary Treatment Strategies in Pulmonary Hypertension: A Clinician's Guide. Annual review of medicine 2026. link 54 Ma JI, Owunna N, Mounsey LA, Jiang NM, Huo X, Zern E et al.. Sex Differences in Pulmonary Hypertension and Associated Right Ventricular Dysfunction. The American journal of cardiology 2026. link 55 Wang X, Li C, Wang S, Zhu Z, Chen Q, Shen R et al.. Utility of inhaled nitric oxide for pulmonary hypertension in cyanotic congenital heart disease: a cohort study with propensity score matching. Medical gas research 2026. link 56 De Bie E, Correa-Jaque P, Jones R, Bogaard HJ, Chan J, Church C et al.. Inflammation and Obesity Correlate in Pulmonary Hypertension but Are Associated with Diverging Outcomes. American journal of respiratory and critical care medicine 2026. link 57 Egenlauf B, Braun M, Schiffer V, Marra AM, Xanthouli P, Harutyunova S et al.. Right ventricular function in pulmonary hypertension and obesity: a cross-sectional cohort study with survival follow-up. Clinical research in cardiology : official journal of the German Cardiac Society 2026. link 58 Hayvaci Canbeyli F, Secgen K, Ezgu FS, Tacoy G, Unlu S, Arabacı HO et al.. The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. Pediatric cardiology 2026. link 59 Zhang X, Chen M, Wang R, Liu R, Gong D, Zhang M et al.. Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension. International journal of molecular sciences 2025. link 60 Huang W, Zheng R, Gong L, Zhang Y, Tan J, Cao X et al.. Roles of Lipid Metabolism in Pulmonary Hypertension: Friend or Foe?. Biomolecules 2025. link 61 Wang M, Lu J, Li X, Xie H, Liang J, Luo J et al.. Construction of an early diagnostic model for pulmonary hypertension based on aging-related signature genes and identification of potential therapeutic targets. Scientific reports 2025. link 62 Dagher C, Akiki M, Swanson K, Carollo B, Chernobelsky E, Farber HW et al.. Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy. The clinical respiratory journal 2025. link 63 Pei Y, Si M, Ma X, Liu S, Zhao F, Zhou R. Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension. Drug design, development and therapy 2025. link 64 Wang YB, Gao L, Wang JX, Mei Z, Fan YL, Gao X et al.. DNMT1 deficiency promotes pulmonary vascular remodeling in pulmonary hypertension through epigenetic upregulation of BMP7. Respiratory research 2025. link 65 Ruan B, Chen M, Zhuang Q, Guan L, Xie W, Wang L et al.. Chest Computed Tomography-Based Radiomics for the Diagnosis and Prognosis of Pulmonary Hypertension. Journal of the American Heart Association 2025. link 66 Gong C, Lan X, Xie Y, Wu X, Wu F, Chen X et al.. Overexpression of PRDX2 alleviates chronic thromboembolic pulmonary hypertension by modulating inflammation and mitophagy. Scientific reports 2025. link 67 Kramer T, Kramer M, Hagist C, Spinler S. Artificial intelligence in pulmonary hypertension: a systematic review. European journal of medical research 2025. link 68 Berra G, Genecand L, Juillet A, Deux JF, Prada P, Müller H et al.. Reversible pulmonary hypertension in a patient diagnosed with scurvy. BMJ case reports 2025. link 69 Wang X, Li S, Hou J, Cao S, Zhang Y, Zhang J et al.. tsRNA-3040b accumulates R-loop to regulate Trim35 transcription, which leads to disordered glycolysis and promotes PAECs proliferation. Cellular & molecular biology letters 2025. link 70 Wang Y, Li X, Huang Z, Duan A, Zhang S, Wang Q et al.. Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension. Clinical and translational science 2025. link 71 Iancu DG, Mares RG, Cristescu L, Suteu RA, Varga A, Tilea I. Inflammation-Based Hematologic Indices as Prognostic Markers in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: A Hypothesis-Generating Registry Study. International journal of molecular sciences 2025. link 72 Yadeta D, Bekele A, Bayisa T, Adem A, Mekonnen D, Guteta S et al.. Clinical characteristics and causes of non-cardiac pulmonary hypertension in two major tertiary teaching hospitals in Ethiopia: a cross-sectional descriptive study. BMC research notes 2025. link 73 Foster B, Khan S, Suarez Gonzalez A, Gillenwater S. Pulmonary Veno-Occlusive Disease: A Comprehensive Review of Diagnostic Challenges, Therapeutic Limitations, and Evolving Management. Advances in respiratory medicine 2025. link 74 Chen Y, Lv Y, Yang M, Qian Z, Jiang X, Jiang Z et al.. The P4HA1/HIF1α feedback loop modulates endothelial dysfunction in pulmonary hypertension. Respiratory research 2025. link 75 Politeski AL, Rico AQL, Cambell J, Cisneros Medrano JG, Witmer B, Gupta R et al.. The Monocrotaline Model of Hypertension Leads to Cachexia in Male but Not Female Mice. Journal of cachexia, sarcopenia and muscle 2025. link 76 Fan L, Davó-Jiménez M, Benefield BC, Beydoun N, Dushfunian D, Cohn S et al.. Cardiovascular MRI-based Biventricular Perfusion Assessment in Two Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Pulmonary Thromboendarterectomy. Radiology. Cardiothoracic imaging 2025. link 77 Venkateshvaran A, Lindow T, Jumatate R, Kovacs A, Ingvarsson A, Lindqvist P et al.. Prognostic Value of Right Ventricular Global Wasted Work in Precapillary Pulmonary Hypertension: A 3D Echocardiographic Study. Echocardiography (Mount Kisco, N.Y.) 2025. link 78 You Z, Huang Q, Zeng L, Tian X, Zhang W, Wei D et al.. Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis. Cellular and molecular life sciences : CMLS 2025. link 79 Rada-Pascual KM, Zúniga-Muñoz AM, Alvarez-Alvarez YQ, Del Valle-Mondragón L, Rubio-Gayosso I, Martínez-Olivares CE et al.. Fenofibrate as a Modulator of the Renin-Angiotensin System in Su/Hx-Induced Pulmonary Arterial Hypertension. International journal of molecular sciences 2025. link 80 Zhang H, Yang B, Liu B, Luo Q, Tang Y, Wang T et al.. Long-term outcomes and prognostic predictors in patients with fibrosing mediastinitis associated pulmonary hypertension: a multicenter cohort study. Orphanet journal of rare diseases 2025. link 81 Xiao Y, Cai Z, Bai M, Wu X, Wang W, Liu R et al.. Harnessing NLRX1: a new frontier in mitigating inflammation in pulmonary hypertension. Respiratory research 2025. link 82 Pan YS, Xu GR, Qu NN, Qin YB, Guan TF, Cao MZ et al.. Exploration of upstream and downstream mechanisms of the TAGLN2 gene in pulmonary arterial hypertension. Medicine 2025. link 83 Qi Y, Liu J, Cui X, Wang Y, Ma M, Zhang H et al.. The Diagnostic Value of Transthoracic Echocardiography Parameters Under the New Diagnostic Criteria for Pulmonary Hypertension. Canadian respiratory journal 2025. link 84 Xing Y, Liu C, Zhang C, Zhou D, Hu B, Jiang Q et al.. Antibiotic-driven and microbiota-targeted therapy for advanced management of pulmonary hypertension. Respiratory research 2025. link 85 Fiscus G, Dagher C, O'Sullivan D, Carollo B, Swanson K, Farber HW et al.. Development of a Tool to Assess the Severity of Pulmonary Hypertension in Patients with Interstitial Lung Disease: A Guide to Assist Therapeutic Choices. Advances in respiratory medicine 2025. link 86 Lehtinen ML, Ropponen J, Kesävuori R, Wilkman E, Ristikankare A, Nykänen A. Bridging to a delayed pulmonary endarterectomy in massive acute-on-chronic pulmonary thromboembolism: a case report. Journal of cardiothoracic surgery 2025. link 87 Guan M, Yang X, Fu L, Zhao X, Hei F. Factors affecting patient outcomes in pulmonary artery thromboendarterectomy under deep hypothermic circulatory arrest and cardiopulmonary bypass support----a single center's experience. BMC cardiovascular disorders 2025. link 88 Shimizu A, Kakeshita K, Imamura T, Murai S, Yamazaki H, Ueno H et al.. Refractory Renovascular Hypertension from Paraganglioma: A Case Report. The American journal of case reports 2025. link 89 Gong X, Sheng Y, Zhang G, Kang S, Liu X, Wang Y et al.. Notoginsenoside R1 Improved Hypoxic Pulmonary Hypertension by Inhibiting Glycolysis-Mediated Pulmonary Arterial Vascular Remodeling. Canadian respiratory journal 2025. link 90 Huang B, Hao Y, Wen Z, Dong J, Jin S, Li H. Role of lipid droplets in pulmonary arterial hypertension: focusing on pulmonary artery smooth muscle cell proliferation. Lipids in health and disease 2025. link 91 Tabi M, Padkins M, Bushari LI, Thaden J, Solomon MA, Kane GC et al.. Echocardiographic Predictors of Mortality in Cardiac Intensive Care Unit Patients With Pulmonary Hypertension. The American journal of cardiology 2025. link 92 Sun L, Li H, Li Y, Li X, Tian H, Liu J et al.. Proteomic insights into platelet dysregulation and pathogenic mechanisms of chronic thromboembolic pulmonary hypertension. Journal of translational medicine 2025. link 93 Blanco I, Torres-Castro R, Piccari L, Garcia AR, Gimeno-Santos E, Ramírez AM et al.. Effects of pulmonary arterial hypertension therapies on arterial oxygenation in patients with pulmonary hypertension associated with lung disease: a systematic review and meta-analysis. BMJ open respiratory research 2025. link 94 Dardi F, Bertozzi R, Ballerini A, Cennerazzo F, Donato F, Guarino D et al.. Phenotyping of patients with mild pulmonary hypertension. Open heart 2025. link 95 Kaur J, Kaur G, Kaur C, Kumar S. Targeted nanosponge-based treatment for pulmonary hypertension: A novel approach. Journal of food and drug analysis 2025. link 96 Zazzeron L, Shimoda K, Lichtenegger P, Moore E, Tattersfield H, Marenco AK et al.. Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice. Journal of the American Heart Association 2025. link 97 Yamada K, Yaoita N, Satoh T, Yamamoto S, Yamada Y, Chiba N et al.. Long-Term Prognostic and Hemodynamic Outcomes of Intensive Immunosuppressive Therapy in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. International journal of rheumatic diseases 2025. link 98 Chen D, Tian D, Jin Q, Zhang L, Zhang X, Li M et al.. The potential of non-invasive remote dielectric sensing in predicting short-term prognosis of patients with pulmonary hypertension. BMC pulmonary medicine 2025. link 99 Li J, Zhou Z, Yu J, Zhong Z, Huang N, Wang Y et al.. Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy. Renal failure 2025. link 100 Mickael C, Kumar R, Fonseca Balladares DC, Nolan K, Lee MH, Kassa B et al.. Role of conventional dendritic cells in schistosomiasis-induced pulmonary hypertension. Clinical science (London, England : 1979) 2025. link

Original source

[1]
Alternative Polyadenylation Signatures Distinguish Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension: Implications for RNA-Based Diagnostics and Therapeutics. — Subramaniam J, Jonnakuti V, Collum SD, Martineau S, Huang KL, Breuils-Bonnet S et al. British journal of biomedical science (2026)
[2]
The resistance-compliance relationship at low pulmonary resistance: Integrating pulmonary wedge pressure into right ventricular load assessment. — Kempton H, Olsen N, Kearney K, Hayward CS, Muller DWM, Adji A Physiological reports (2026)
[3]
Residual physiological abnormalities after pulmonary endarterectomy and balloon pulmonary angioplasty in CTEPH. — Calé R, Ferreira F, Martinho M, Alegria S, Repolho D, Pereira AR et al. PloS one (2026)
[4]
PAH-former: Transfer learning for efficient discovery of pulmonary arterial hypertension-associated genes. — Kawakami T, Hosokawa S, Ito M, Kurozumi A, Tanaka R, Minatsuki S et al. PloS one (2026)
[5]
TRPC Channels as Mediators of Hypoxia-Induced Pulmonary Hypertension in Obstructive Sleep Apnea. — Torres YP, Aristizábal-Pachón AF, Otero L International journal of molecular sciences (2026)
[6]
Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension. — Onofre MESF, Santos RT, Rocha NN, Caldeira DAF, Silva JD, Silva CMD et al. International journal of molecular sciences (2026)
[7]
Pulmonary rehabilitation for pulmonary hypertension in high-altitude areas: a mixed-methods study of medical staff's perspectives. — Li W, Zheng Y, Fan M, Sun Y, Li X, Zhao Z et al. Frontiers in public health (2026)
[8]
Monocrotaline toxicity in rats: decreased lung retinol and elevated alpha-tocopherol levels in lung and liver. — Baybutt RC, Smith VB, Kearns DG, Stafford SB Journal of nutritional science (2026)
[9]
Previous resistance exercise training mitigates progression of right ventricle dysfunction and remodeling in male rats with pulmonary arterial hypertension. — Portes AMO, de Moura AG, de Jesus Silva F, Guimarães-Ervilha LO, de Freitas MO, Soares LL et al. Physiological reports (2026)
[10]
Evaluating the Impact of Inspiratory Muscle Training on Respiratory Function and Exercise Capacity in Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. — Alrashedi S, Alharbi L, Alotaibi M, Alzahrani I, Jad A, Aldoboke Q et al. Advances in respiratory medicine (2026)
[11]
The Vascular-Immune Cells Crosstalk and Microenvironment in Pulmonary Hypertension. — Navarro-Llinares L, García-León B, de la Bastida-Casero L, Oliver E Comprehensive Physiology (2026)
[12]
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. — Reddy YNV, Frantz RP, Miranda WR, Asokan AK, Varma R, Rischard F et al. Circulation (2026)
[13]
The First 1000 Days: Maternal Nutrient Intake-A Window of Opportunity for Pulmonary Hypertension-A Narrative Review. — Luca AC, Roșu ST, Diaconescu C, Mîndru DE, Gavrilovici C, Vizireanu A et al. Nutrients (2026)
[14]
Integrative Machine Learning and Experimental Validation Identify FIS1 as a Candidate Biomarker Linked to Mitochondrial Dynamics in Pulmonary Hypertension. — Zhang Y, Dai Q, Gong L, Zheng R, Huang W, Wang F et al. Cells (2026)
[15]
Murine Aortopulmonary Shunt Model of Flow-Driven Pulmonary Hypertension-Brief Report. — Cai D, Zhou R, Fujise K, Chen SY Arteriosclerosis, thrombosis, and vascular biology (2026)
[16]
Beta arrestin 1 is a key regulator of pulmonary vascular tone. — Lebender LF, Seidinger A, Matthey M, Dyck B, Schlamm C, Kaddoura A et al. Proceedings of the National Academy of Sciences of the United States of America (2026)
[17]
Inactivation of the Phosphatase Activity of Soluble Epoxide Hydrolase Modulates SIRT3 and Attenuates Experimental Pulmonary Hypertension. — Leuillier M, Chelgham M, Messaoudi H, Tu L, Ménoret S, Thuillet R et al. Comprehensive Physiology (2026)
[18]
Identification and genetic validation of potential therapeutic targets for pulmonary hypertension through multi-omics causal inference. — Wu C, Zhao W, Zhu X, Li Y, Chen Z, Yan X Medicine (2026)
[19]
Mindfulness-Based Self-Management Program Using a Mobile App for Patients With Pulmonary Hypertension: Single-Arm Feasibility Study. — Takita Y, Morishita J, Park S, Goda A, Inami T, Kikuchi H et al. JMIR cardio (2026)
[20]
IL-6 and TGF-β1 as biomarkers of schistosomiasis-associated pulmonary hypertension in a murine model. — Roque AC, Stockmann IS, Acencio MMP, Silva CSR, Espírito-Santo MCD, Pinto PLS et al. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas (2026)
[21]
The hypoxic tight-skin mouse model of Group 3 pulmonary hypertension. — Chi L, Foley AE, Goodarzi G, Volchuk A, Fuerte KPB, Tracey KJ et al. Scientific reports (2026)
[22]
Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers. — Shaukat M, Grünig E, Haas S, Haas J, Panahi M, Granzow M et al. Scientific reports (2026)
[23]
Sotatercept in Pulmonary Arterial Hypertension: Molecular Mechanisms, Clinical Evidence, and Emerging Role in Reverse Remodelling. — Tilea I, Iancu DG, Fira-Mladinescu O, Bertici N, Varga A International journal of molecular sciences (2026)
[24]
Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism. — Batum Ö, Ayık Türk M, Varol Y, Özyılmaz B, Akarçay AE, Dirican N et al. International journal of molecular sciences (2026)
[25]
Deciphering the Counterintuitive Role of Vascular Endothelial Growth Factor Signaling Pathways in Pulmonary Arterial Hypertension. — Scagliola R International journal of molecular sciences (2026)
[26]
Mechanisms Underlying Altitude-Induced and Group 3 Pulmonary Hypertension. — Milano G, Ottolenghi S, Zubieta-Calleja G, Beghetti M, Samaja M International journal of molecular sciences (2026)
[27]
Effects of Sodium Butyrate Forms on Carcass Performance, Pulmonary Hypertension, Metabolic Health and Oxidative-Inflammatory Responses in Broiler Chickens Under Cold Stress at High Altitude. — Ahmadipour B, Pat S, Khajali F, Hassanpour H Veterinary medicine and science (2026)
[28]
Inducible Ift88-deficient mice show features consistent with mild pulmonary hypertension. — Garcia SM, Lantz BJ, Wagner HJ, Jones DT, Arechiga-Gonzalez R, Howard TA et al. Physiological reports (2026)
[29]
Patient-Specific Lumped-Parameter Model for Quantifying Vessel-Specific Remodeling and Predicting Right Ventricular Function in Pulmonary Hypertension. — Lechuga CG, Kachabi A, Colebank MJ, Korcarz CE, Raza F, Chesler NC Comprehensive Physiology (2026)
[30]
Role of hsa-miR-122-5p in chronic thromboembolic pulmonary hypertension and chronic thromboembolic disease: Targeting PIK3CG in the PI3K/Akt signaling pathway. — Chen R, Ye W, Yang Y, Liao H, Sun T, Liao W et al. Medicine (2026)
[31]
AI-assisted multimodal assessment for right ventricular function from echocardiography predicts mortality in patients with pulmonary hypertension and right heart failure. — Mou H, Zhang G, Xiu L, Zhao Q, Zhang R, Liu GA Scientific reports (2026)
[32]
Histone deacetylase 3 promotes hypoxia-induced human pulmonary arterial smooth muscle cell proliferation by modulating the CSF2-JAK2-STAT5 signaling pathway. — Zhang J, Fan Y, Gao Y, Jin Y Human cell (2026)
[33]
Roles of the Altitude-Adapted Immune Microenvironment in Pulmonary Vascular Remodeling in High-Altitude Pulmonary Hypertension: A Review. — Li Y, Xing H, Liu Y, Li F, Yang D, Miao Q et al. Medical science monitor : international medical journal of experimental and clinical research (2026)
[34]
Zinc-Induced PKCδ-dependent Phosphorylation of MTF-1 Promotes Pulmonary Vascular Remodeling in Hypoxic Pulmonary Hypertension. — Chen A, Yan Y, Cao R, Cai K, Lian G, Cai W et al. International journal of biological sciences (2026)
[35]
The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension. — Hernandez M, Winicki NM, Puerta CD, Lakshminarayanan S, Zhang Y, Ramirez-Sanchez I et al. Nature medicine (2026)
[36]
Pulmonary hypertension caused by fibrosing mediastinitis: A case report and literature review. — Yue K, Qu X, Zhang F, Zhao M Medicine (2026)
[37]
Mesenchymal stromal cells alleviate pulmonary arterial hypertension by suppressing pulmonary arterial adventitial fibroblast activation and extracellular matrix remodeling via the SOCS3/STAT3 pathway. — Wang J, Jin J, Zhang M, Chen X, Du S, Mao X et al. Stem cell research & therapy (2026)
[38]
Bilateral lung transplantation with simultaneous aortic replacement using donor aorta in a patient with pulmonary arterial hypertension and patent ductus arteriosus. — Ishida N, Oishi H, Niikawa H, Suzuki T, Notsuda H, Hirama T et al. Journal of cardiothoracic surgery (2026)
[39]
Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study. — Kam THH, Kam KKH, Wong MKL, Yan BPY, Tan G BMC pulmonary medicine (2026)
[40]
Comprehensive profiling of lactylation-associated genes in pulmonary hypertension through bulk and single-cell RNA sequencing integration. — Han R, Wang Y, Lu X, Li W, Wu W, Wang W et al. Respiratory research (2026)
[41]
Expert consensus on patient engagement strategies for improving patient activation and shared decision making in pulmonary arterial hypertension. — Ryan JJ, Wilson M, Saggar R, Benninger C, Bridge D, Cho M et al. Journal of the American Association of Nurse Practitioners (2026)
[42]
Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment. — Yogeswaran A, Annis JS, Fünderich M, Wilhelm J, Kiely DG, Howard L et al. EBioMedicine (2026)
[43]
Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review. — Habib NG, Adhia A, Lopez D, Sandros M, Guichard P Advances in therapy (2026)
[44]
Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension. — Aguado B, Ruffenach G, Lacoste-Palasset T, Görlach A, Riou M, Gourmelon M et al. Circulation. Heart failure (2026)
[45]
Inactivation of AXL in Cardiac Fibroblasts Alleviates Right Ventricular Remodeling in Pulmonary Hypertension. — Wu LW, Chen M, Jiang CY, Jiang DJ, Zhang X, Xu XH et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026)
[46]
GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension. — Prabhakar A, De Bie EM, DesJardin JT, Ghatpande P, Gräf S, Howard LS et al. The Journal of clinical investigation (2026)
[47]
Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies. — Melendres-Groves LD, Channick RN, Chin KM, McLaughlin VV, MacDonald G, Martin N et al. Advances in therapy (2026)
[48]
Endothelial Heterogeneity in Pulmonary Hypertension. — Zhao H, Chakinala MM, Fallon MB, Lin SM, Lee JS, Dai Z Arteriosclerosis, thrombosis, and vascular biology (2026)
[49]
Transitioning Between Treprostinil Formulations: Evidence and Strategies. — Clarke M, Ataya A, Turkin AM, Parikh R, Davis K, Miller CE et al. Advances in therapy (2026)
[50]
Systemic prostacyclin analogues in pulmonary hypertension are associated with reduced risk of age-related macular degeneration: a cohort study. — Eilon E, Lishinsky-Fischer N, Levy J Eye (London, England) (2026)
[51]
A Novel Computational Pipeline for Acquiring Pressure-Volume Hemodynamics of the Right Ventricle in Pulmonary Hypertension. — Moon GS, Scheel PJ, Montovano M, Kaushik M, Buchanan C, Friedman SH et al. JACC. Heart failure (2026)
[52]
Impact of Lipid Profile Alterations on the Right Heart Function and Prognosis in Pre-Capillary Pulmonary Hypertension Patients: A Prospective Cohort Study. — Guo J, Zhao J, Wang J, Li Y, He J, Chen C et al. Respirology (Carlton, Vic.) (2026)
[53]
Contemporary Treatment Strategies in Pulmonary Hypertension: A Clinician's Guide. — Budhram B, Chung S, Humbert M, Horn E Annual review of medicine (2026)
[54]
Sex Differences in Pulmonary Hypertension and Associated Right Ventricular Dysfunction. — Ma JI, Owunna N, Mounsey LA, Jiang NM, Huo X, Zern E et al. The American journal of cardiology (2026)
[55]
Utility of inhaled nitric oxide for pulmonary hypertension in cyanotic congenital heart disease: a cohort study with propensity score matching. — Wang X, Li C, Wang S, Zhu Z, Chen Q, Shen R et al. Medical gas research (2026)
[56]
Inflammation and Obesity Correlate in Pulmonary Hypertension but Are Associated with Diverging Outcomes. — De Bie E, Correa-Jaque P, Jones R, Bogaard HJ, Chan J, Church C et al. American journal of respiratory and critical care medicine (2026)
[57]
Right ventricular function in pulmonary hypertension and obesity: a cross-sectional cohort study with survival follow-up. — Egenlauf B, Braun M, Schiffer V, Marra AM, Xanthouli P, Harutyunova S et al. Clinical research in cardiology : official journal of the German Cardiac Society (2026)
[58]
The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. — Hayvaci Canbeyli F, Secgen K, Ezgu FS, Tacoy G, Unlu S, Arabacı HO et al. Pediatric cardiology (2026)
[59]
Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension. — Zhang X, Chen M, Wang R, Liu R, Gong D, Zhang M et al. International journal of molecular sciences (2025)
[60]
Roles of Lipid Metabolism in Pulmonary Hypertension: Friend or Foe? — Huang W, Zheng R, Gong L, Zhang Y, Tan J, Cao X et al. Biomolecules (2025)
[61]
Construction of an early diagnostic model for pulmonary hypertension based on aging-related signature genes and identification of potential therapeutic targets. — Wang M, Lu J, Li X, Xie H, Liang J, Luo J et al. Scientific reports (2025)
[62]
Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy. — Dagher C, Akiki M, Swanson K, Carollo B, Chernobelsky E, Farber HW et al. The clinical respiratory journal (2025)
[63]
Preparation of 18β-Glycyrrhetinic Acid Liposome and Its Therapeutic Effect on Pulmonary Arterial Hypertension. — Pei Y, Si M, Ma X, Liu S, Zhao F, Zhou R Drug design, development and therapy (2025)
[64]
DNMT1 deficiency promotes pulmonary vascular remodeling in pulmonary hypertension through epigenetic upregulation of BMP7. — Wang YB, Gao L, Wang JX, Mei Z, Fan YL, Gao X et al. Respiratory research (2025)
[65]
Chest Computed Tomography-Based Radiomics for the Diagnosis and Prognosis of Pulmonary Hypertension. — Ruan B, Chen M, Zhuang Q, Guan L, Xie W, Wang L et al. Journal of the American Heart Association (2025)
[66]
Overexpression of PRDX2 alleviates chronic thromboembolic pulmonary hypertension by modulating inflammation and mitophagy. — Gong C, Lan X, Xie Y, Wu X, Wu F, Chen X et al. Scientific reports (2025)
[67]
Artificial intelligence in pulmonary hypertension: a systematic review. — Kramer T, Kramer M, Hagist C, Spinler S European journal of medical research (2025)
[68]
Reversible pulmonary hypertension in a patient diagnosed with scurvy. — Berra G, Genecand L, Juillet A, Deux JF, Prada P, Müller H et al. BMJ case reports (2025)
[69]
tsRNA-3040b accumulates R-loop to regulate Trim35 transcription, which leads to disordered glycolysis and promotes PAECs proliferation. — Wang X, Li S, Hou J, Cao S, Zhang Y, Zhang J et al. Cellular & molecular biology letters (2025)
[70]
Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension. — Wang Y, Li X, Huang Z, Duan A, Zhang S, Wang Q et al. Clinical and translational science (2025)
[71]
Inflammation-Based Hematologic Indices as Prognostic Markers in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: A Hypothesis-Generating Registry Study. — Iancu DG, Mares RG, Cristescu L, Suteu RA, Varga A, Tilea I International journal of molecular sciences (2025)
[72]
Clinical characteristics and causes of non-cardiac pulmonary hypertension in two major tertiary teaching hospitals in Ethiopia: a cross-sectional descriptive study. — Yadeta D, Bekele A, Bayisa T, Adem A, Mekonnen D, Guteta S et al. BMC research notes (2025)
[73]
Pulmonary Veno-Occlusive Disease: A Comprehensive Review of Diagnostic Challenges, Therapeutic Limitations, and Evolving Management. — Foster B, Khan S, Suarez Gonzalez A, Gillenwater S Advances in respiratory medicine (2025)
[74]
The P4HA1/HIF1α feedback loop modulates endothelial dysfunction in pulmonary hypertension. — Chen Y, Lv Y, Yang M, Qian Z, Jiang X, Jiang Z et al. Respiratory research (2025)
[75]
The Monocrotaline Model of Hypertension Leads to Cachexia in Male but Not Female Mice. — Politeski AL, Rico AQL, Cambell J, Cisneros Medrano JG, Witmer B, Gupta R et al. Journal of cachexia, sarcopenia and muscle (2025)
[76]
Cardiovascular MRI-based Biventricular Perfusion Assessment in Two Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Pulmonary Thromboendarterectomy. — Fan L, Davó-Jiménez M, Benefield BC, Beydoun N, Dushfunian D, Cohn S et al. Radiology. Cardiothoracic imaging (2025)
[77]
Prognostic Value of Right Ventricular Global Wasted Work in Precapillary Pulmonary Hypertension: A 3D Echocardiographic Study. — Venkateshvaran A, Lindow T, Jumatate R, Kovacs A, Ingvarsson A, Lindqvist P et al. Echocardiography (Mount Kisco, N.Y.) (2025)
[78]
Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis. — You Z, Huang Q, Zeng L, Tian X, Zhang W, Wei D et al. Cellular and molecular life sciences : CMLS (2025)
[79]
Fenofibrate as a Modulator of the Renin-Angiotensin System in Su/Hx-Induced Pulmonary Arterial Hypertension. — Rada-Pascual KM, Zúniga-Muñoz AM, Alvarez-Alvarez YQ, Del Valle-Mondragón L, Rubio-Gayosso I, Martínez-Olivares CE et al. International journal of molecular sciences (2025)
[80]
Long-term outcomes and prognostic predictors in patients with fibrosing mediastinitis associated pulmonary hypertension: a multicenter cohort study. — Zhang H, Yang B, Liu B, Luo Q, Tang Y, Wang T et al. Orphanet journal of rare diseases (2025)
[81]
Harnessing NLRX1: a new frontier in mitigating inflammation in pulmonary hypertension. — Xiao Y, Cai Z, Bai M, Wu X, Wang W, Liu R et al. Respiratory research (2025)
[82]
Exploration of upstream and downstream mechanisms of the TAGLN2 gene in pulmonary arterial hypertension. — Pan YS, Xu GR, Qu NN, Qin YB, Guan TF, Cao MZ et al. Medicine (2025)
[83]
The Diagnostic Value of Transthoracic Echocardiography Parameters Under the New Diagnostic Criteria for Pulmonary Hypertension. — Qi Y, Liu J, Cui X, Wang Y, Ma M, Zhang H et al. Canadian respiratory journal (2025)
[84]
Antibiotic-driven and microbiota-targeted therapy for advanced management of pulmonary hypertension. — Xing Y, Liu C, Zhang C, Zhou D, Hu B, Jiang Q et al. Respiratory research (2025)
[85]
Development of a Tool to Assess the Severity of Pulmonary Hypertension in Patients with Interstitial Lung Disease: A Guide to Assist Therapeutic Choices. — Fiscus G, Dagher C, O'Sullivan D, Carollo B, Swanson K, Farber HW et al. Advances in respiratory medicine (2025)
[86]
Bridging to a delayed pulmonary endarterectomy in massive acute-on-chronic pulmonary thromboembolism: a case report. — Lehtinen ML, Ropponen J, Kesävuori R, Wilkman E, Ristikankare A, Nykänen A Journal of cardiothoracic surgery (2025)
[87]
Factors affecting patient outcomes in pulmonary artery thromboendarterectomy under deep hypothermic circulatory arrest and cardiopulmonary bypass support----a single center's experience. — Guan M, Yang X, Fu L, Zhao X, Hei F BMC cardiovascular disorders (2025)
[88]
Refractory Renovascular Hypertension from Paraganglioma: A Case Report. — Shimizu A, Kakeshita K, Imamura T, Murai S, Yamazaki H, Ueno H et al. The American journal of case reports (2025)
[89]
Notoginsenoside R1 Improved Hypoxic Pulmonary Hypertension by Inhibiting Glycolysis-Mediated Pulmonary Arterial Vascular Remodeling. — Gong X, Sheng Y, Zhang G, Kang S, Liu X, Wang Y et al. Canadian respiratory journal (2025)
[90]
Role of lipid droplets in pulmonary arterial hypertension: focusing on pulmonary artery smooth muscle cell proliferation. — Huang B, Hao Y, Wen Z, Dong J, Jin S, Li H Lipids in health and disease (2025)
[91]
Echocardiographic Predictors of Mortality in Cardiac Intensive Care Unit Patients With Pulmonary Hypertension. — Tabi M, Padkins M, Bushari LI, Thaden J, Solomon MA, Kane GC et al. The American journal of cardiology (2025)
[92]
Proteomic insights into platelet dysregulation and pathogenic mechanisms of chronic thromboembolic pulmonary hypertension. — Sun L, Li H, Li Y, Li X, Tian H, Liu J et al. Journal of translational medicine (2025)
[93]
Effects of pulmonary arterial hypertension therapies on arterial oxygenation in patients with pulmonary hypertension associated with lung disease: a systematic review and meta-analysis. — Blanco I, Torres-Castro R, Piccari L, Garcia AR, Gimeno-Santos E, Ramírez AM et al. BMJ open respiratory research (2025)
[94]
Phenotyping of patients with mild pulmonary hypertension. — Dardi F, Bertozzi R, Ballerini A, Cennerazzo F, Donato F, Guarino D et al. Open heart (2025)
[95]
Targeted nanosponge-based treatment for pulmonary hypertension: A novel approach. — Kaur J, Kaur G, Kaur C, Kumar S Journal of food and drug analysis (2025)
[96]
Prolonged Postnatal Hypoxia Impairs Lung Development and Causes Severe Pulmonary Hypertension in Mice. — Zazzeron L, Shimoda K, Lichtenegger P, Moore E, Tattersfield H, Marenco AK et al. Journal of the American Heart Association (2025)
[97]
Long-Term Prognostic and Hemodynamic Outcomes of Intensive Immunosuppressive Therapy in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. — Yamada K, Yaoita N, Satoh T, Yamamoto S, Yamada Y, Chiba N et al. International journal of rheumatic diseases (2025)
[98]
The potential of non-invasive remote dielectric sensing in predicting short-term prognosis of patients with pulmonary hypertension. — Chen D, Tian D, Jin Q, Zhang L, Zhang X, Li M et al. BMC pulmonary medicine (2025)
[99]
Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy. — Li J, Zhou Z, Yu J, Zhong Z, Huang N, Wang Y et al. Renal failure (2025)
[100]
Role of conventional dendritic cells in schistosomiasis-induced pulmonary hypertension. — Mickael C, Kumar R, Fonseca Balladares DC, Nolan K, Lee MH, Kassa B et al. Clinical science (London, England : 1979) (2025)